MedExplorer is returning with a new site shortly.
NovoLog
http://novolog.com
NovoLog®, the new rapid-acting insulin analog from Novo Nordisk, is now available in the United States for the treatment of diabetes. NovoLog® is the first insulin analog approved for pump use. NovoLog® can be used in external pump systems suitable for continuous subcutaneous insulin infusion (CSII). NovoLog® has faster absorption, a faster onset and shorter duration of action than regular human insulin. This makes NovoLog® well suited for mealtime dosing to control postprandial glycemia, which is the rise in blood sugar following consumption of food. Find out more here.
Back to Previous Page
Choose Your Letter:
[ A | B | C | D | E | F | G | H
| I | J | K | L | M | N | O | P
| Q | R | S | T | U | V | W | X
| Y | Z ]
© 1996 - 2025 - MedExplorer. All Rights Reserved.
Reproduction in whole or in
part in any form or medium without express written permission of MedExplorer Inc. is
prohibited. MedExplorer and the MedExplorer logos are trademarks of MedExplorer Inc.
MedExplorer assumes no liability for any information provided through this website or
respective links. Anyone using this information does so of their own volition and at
their own risk. Should you require information in regards to a specific medical condition,
please contact your family physician or other appropriate physician. Specific Medical Advice
will not be provided and MedExplorer urges you to visit a qualified physician and/or in the
event of an emergency contact your local emergency services or seek immediate care at an
emergency department.